The MIT Center for Collective Intelligence and MilliporeSigma brought together the thought-power of gurus in science, healthcare, public policy and other sectors to answer the question: how do we apply what we have learned from the COVID-19 pandemic for the future?
The Glycogen Storage Disease Program at Connecticut Children’s and UConn Health reported success in a Phase I/II trial of a gene therapy for GSD-Ia. The gene therapy is developed with Ultragenyx and is dubbed DTX401.
Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.
Ceptur Therapeutics – based in Hillsborough, NJ, Philadelphia and Copenhagen – closed on a Series A financing round worth $75 million.
A three-dose course of AstraZeneca’s Covid-19 vaccine is effective against the rapidly spreading Omicron coronavirus variant, the pharmaceutical company said on December 23, citing data from an Oxford University lab study.
American chemist and former Harvard University professor Dr. Charles Lieber was convicted by a federal jury after being found guilty of lying to the U.S. government about his questionable ties with the People’s Republic of China.
A team of Yale researchers found a key to unlocking the deadly mystery of brain aneurysms in adults.
Researchers from Harvard University and the U.S. Department of Veterans Affairs (VA) found that the Moderna mRNA vaccine was slightly better than the Pfizer-BioNTech vaccine.
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University identified an antibody that attacks SARS-CoV-2, the virus that causes COVID-19, but also its variants and other types of coronaviruses.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
